Skip to Main Content

Active Research Trials

Local Physicians Participating as Investigators in Cancer Clinical Trials

Principal Investigators

Mohamad Kassar, M.D.
Erwin Robin, M.D.

Sub-Investigators

Neeru Bose, M.D.
Brian Blonigen, M.D.
Barbara Fuller, M.D.
Neel Shah, M.D.
George E. Sloan, M.D.
Peter Tothy, M.D.
Andrej Zajac, M.D.
Amer Sidani, M.D.
Sania Raza, M.D.
Mary Nicholson, M.D.
Eduardo Braun, M.D.

Agendia’s MammaPrint® Recommended by ASCO Breast Cancer Guideline in Focused Update Based on Landmark MINDACT Trial Data

Active Research Trials 

Breast

Trial Name: Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)
Trial Number: SWOG S1207

Trial Name: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Trial Number: NRG BR003

Trial Name: A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Trial Number: NSABP B-55/BIG 6-13

Trial Name: A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK3475) plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)
Trial Number: MK3475-355

Lung

Trial Name: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Trial Number: ALCHEMIST (A081105)

Trial Name: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Trial Number: ALCHEMIST (E4512)

Trial Name: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Trial Number: ALCHEMIST (A151216)

Trial Name: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)
Trial Number: ALCHEMIST (EA5142)

Trial Name: A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)
Trial Number: S1400

Trial Name: A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)
Trial Number: S1400I

Trial Name: A Randomized, Double-Blind, Phase III Study of Platinum+ Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)
Trial Number: MK-3475-189

Multiple Myeloma

Trial Name: Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma
Trial Number: ECOG E1A11

Pancreas

Trial Name: Phase II Randomized, Double-Blind Stufy of mFOLFIRINOX plus Ramucirumab versus mFOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients
Trial Number: HCRN GI14-198

Urothelial (Bladder, Urethra, Ureter)

Trial Name: A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182
Trial Number: GU14-182

NOTE: Trials open and close regularly at different times. To make sure a trial is still open, call 219-836-6875. 

It takes 14 years for an experimental drug to travel from the laboratory to U.S. consumers. The longest part of that process is finding people to participate in each phase of clinical trials. The more people who take part, the faster we will find better ways to treat and prevent cancer.

The purpose of the cancer research clinical trials offered at our local hospitals is to gather and evaluate information about new medications that are not yet approved by the FDA. Sometimes, a clinical trial will involve a drug already approved by the FDA for one purpose, but that is being evaluated for another use.

It is important to note that every person participating in a cancer clinical trial receives treatment. While the word placebo may be included in the trial description, patients receive, at minimum, the best standard treatment in conjunction with the study medications. Placebo in these cases does NOT mean the patient is not receiving any treatment.

People choose to participate in clinical trials for many reasons. Some have exhausted all other therapy options and wish to try experimental treatment to help prolong or improve quality of life. Others wish to have access to new therapies that may benefit them, with faster healing or less side effects. Still others feel a strong sense of commitment to helping advance cancer research and help identify new therapies for those diagnosed in the future.

The Community Cancer Foundation sponsors research trials at the three hospitals of the Community Healthcare System: Community Hospital in Munster; St. Catherine Hospital in East Chicago; and St. Mary Medical Center in Hobart. The Foundation provides area residents with access to...

  • Phase II clinical trials sponsored by the Hoosier Oncology Group (HOG) for a variety of metastatic cancers.
  • Phase III clinical trials sponsored by the Cancer Trials Support Unit (CTSU) supported by the National Cancer Institute for most cancer sites.
  • Other clinical trials sponsored by pharmaceutical companies.